Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy
Open Access
- 26 August 2010
- journal article
- Published by Wiley in BJU International
- Vol. 106 (6) , 809-814
Abstract
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE: To explore whether the number of unfavourable pretreatment risk factors predicts cause‐specific mortality in men treated with prostate brachytherapy. PATIENTS AND METHODS: Between April 1995 and March 2006, 739 patients were treated who had at least one of the following adverse risk factors: pretreatment prostate‐specific antigen (PSA) level of >10 ng/mL, a Gleason score of ≥7, clinical stage ≥T2b, or a PSA velocity (PSAV) of >2 ng/mL/year. Supplemental external beam radiotherapy (EBRT) was delivered to 464 (62.8%) men and 301 (40.7%) received androgen deprivation therapy (ADT). Of men with more than two risk factors, 87% received EBRT and 62% received ADT. RESULTS: The biochemical progression‐free survival (bPFS), cause‐specific survival (CSS) and overall survival for all patients were 95.0%, 97.9% and 70.0% at 12 years. Men with three or four risk factors had a prostate cancer‐specific mortality (PCSM) at 12 years of 5.3%, vs 1.7% for men with one or two risk factors ( P = 0.006). When ‘percentage of positive biopsy cores >50%’ replaced PSAV as a risk factor, men with two or more risk factors had a PCSM of 8.9%, vs 1.0% for men with one or two risk factors ( P = 0.001). There was no difference in all‐cause mortality between the groups in either analysis. CONCLUSION: Multimodal brachytherapy results in high rates of bPFS and CSS, even for men with several unfavourable risk factors. Men with two or more unfavourable risk factors had a slightly greater risk of PCSM and no difference in all‐cause mortality. The presence of three or four unfavourable intermediate‐risk factors does not appear to clearly identify a group that requires further treatment intensification, although the percentage of positive cores might be more predictive than PSAV.Keywords
This publication has 28 references indexed in Scilit:
- Predicting Prostate Cancer Mortality Among Men With Intermediate to High-Risk Disease and Multiple Unfavorable Risk FactorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Primary Causes of Death After Permanent Prostate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Comparison of 7-Year Outcomes Between LDR Brachytherapy and High Dose IMRT for Patients With Clinically Localized Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Hypofractionated Intensity-Modulated Radiotherapy (70 Gy at 2.5 Gy Per Fraction) for Localized Prostate Cancer: Cleveland Clinic ExperienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External BeamInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Changing the patterns of failure for high-risk prostate cancer patients by optimizing local controlInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006